Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
Clinical trial NCT01151423 · COMPLETED
Trial details
- NCT number
- NCT01151423
- Sponsor
- Ablynx, a Sanofi company
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2011-01-01
- Primary completion
- 2014-03-01
- Enrollment
- 75
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.